Media stories about Interpace Diagnostics Gr (NASDAQ:IDXG) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Interpace Diagnostics Gr earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the business services provider an impact score of 45.0314685633131 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of IDXG stock traded down $0.02 during trading on Monday, reaching $0.90. The company’s stock had a trading volume of 129,485 shares, compared to its average volume of 544,673. The stock has a market capitalization of $25.64, a P/E ratio of -1.11 and a beta of 1.73. Interpace Diagnostics Gr has a 1-year low of $0.72 and a 1-year high of $4.45.
A number of brokerages have weighed in on IDXG. Maxim Group set a $3.00 price target on shares of Interpace Diagnostics Gr and gave the company a “buy” rating in a research report on Wednesday, March 28th. HC Wainwright set a $3.00 price target on shares of Interpace Diagnostics Gr and gave the company a “buy” rating in a research report on Friday. ValuEngine cut shares of Interpace Diagnostics Gr from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Finally, Laidlaw began coverage on shares of Interpace Diagnostics Gr in a research report on Thursday, February 22nd. They set a “buy” rating and a $4.50 price target for the company.
COPYRIGHT VIOLATION NOTICE: “Interpace Diagnostics Gr (IDXG) Given Daily Media Impact Rating of 0.23” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/09/interpace-diagnostics-gr-idxg-given-daily-media-impact-rating-of-0-23.html.
Interpace Diagnostics Gr Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay.
Receive News & Ratings for Interpace Diagnostics Gr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Gr and related companies with MarketBeat.com's FREE daily email newsletter.